An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains ...

The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who are refractory to other treatments.

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...

Growing numbers of invasive raccoon dogs are preying on baby sea turtles on the beaches of Yakushima island, one of the world ...

A mosquito-borne virus more common in South America has been detected in the United States. Health officials say the ...

Instagram/@mandymooremm Mandy Moore has become the talk of social media after recent photos of her surfaced online, sparking ...

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to the Poster presentation session. Dr. Aaron Holmes presented the poster ...

Objective Macrophage activation syndrome (MAS), a subtype of secondary haemophagocytic lymphohistiocytosis (HLH), is a rare ...

An expert discusses how rilzabrutinib’s oral administration and broad tolerability make it a practical treatment option while ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...

Community-acquired pneumonia is a major global health challenge that disproportionately affects vulnerable populations, ...